Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations

Ceftolozane/tazobactam and ceftazidime/avibactam are 2 novel β-lactam/β-lactamase combination antibiotics. The antimicrobial spectrum of activity of these antibiotics includes multidrug-resistant (MDR) gram-negative bacteria (GNB), including Pseudomonas aeruginosa. Ceftazidime/avibactam is also active against carbapenem-resistant Enterobacteriaceae that produce Klebsiella pneumoniae carbapenemases. However, avibactam does not inactivate metallo-β-lactamases such as New Delhi metallo-β-lactamases. Both ceftolozane/tazobactam and ceftazidime/avibactam are only available as intravenous formulations and are dosed 3 times daily in patients with normal renal function. Clinical trials showed noninferiority to…

• UD
  U.S. Department of Veterans Affairs

  Award: 1I01BX001974
• A
  AstraZeneca
• S
  Sanofi
• AP
  Astellas Pharma
• NI
  National Institutes of Health

  Awards: R01AI100560, UM1AI104681, R01AI072219, R01AI063517
• GR
  Geriatric Research Education and Clinical Center
• NI
  National Institute of Allergy and Infectious Diseases

  Awards: R01AI063517, UM1AI104681, R01AI100560, R01AI072219
• NC
  NIH Clinical Center

  Award: UM1AI104681